Novartis’ former IP chief urges innovative pharma to emulate high-tech patent strategies

Novartis’ former IP chief urges innovative pharma to emulate high-tech patent strategies

The former global head of pharma intellectual property at Novartis has told IAM that life sciences companies should consider a more tech-like approach to IP management, involving licensing out development patents to competitors, rather than seeking…

Unlock unlimited access to all IAM content